NCT07197944View on ClinicalTrials.gov

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

October 23, 2025

Primary Completion Date

October 23, 2028

Study Completion Date

February 28, 2032

Conditions

Short Bowel Syndrome

Interventions

DRUG

Glepaglutide

Subcutaneous (SC) injections twice weekly

OTHER

Placebo

SC injections twice weekly

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Zealand Pharma

INDUSTRY

NCT07197944 - Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Biotech Hunter | Biotech Hunter